NET PROFIT FORECAST: Net profit is expected to rise to 1.67 billion pounds from 1.05 billion pounds, according to a consensus provided by the company. London-listed shares in GSK are up 4.1% since the ...

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.